LCRF Offers $150K Grant for Lung Cancer Prevention & Early Detection Research

Deadline: 10-Mar-2026 The Lung Cancer Research Foundation (LCRF) Early Detection and Prevention Grant provides up to $150,000 over two years for innovative research aimed at identifying lung cancer at its earliest, most treatable stages. This grant supports early-career investigators worldwide focusing on biomarkers, liquid biopsies, and screening implementation science. The 2026 application cycle begins with a mandatory Letter of Intent (LOI) due by March 10, 2026. The Lung Cancer Research Foundation (LCRF) provides dedicated funding for research projects that facilitate the prevention or early detection of lung cancer. By focusing on the “pre-neoplastic” stage and improving screening uptake, this program aims to significantly increase long-term survival and survivorship for both Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC). Why It Matters: The Case for Early Intervention Lung cancer remains the leading cause of cancer-related deaths worldwide, often because it is diagnosed at advanced stages. Survival Rates: Detection at Stage I or II drastically improves the 5-year survival rate compared to Stage IV. Screening Gaps: Despite proven benefits, the uptake of Low-Dose CT (LDCT) screening remains low; this grant funds implementation science to close that gap. Technological Innovation: Support for liquid biopsies and computational imaging allows for non-invasive, more accurate diagnostic pathways. Key Concepts and Semantic Terms Pre-neoplastic Lesions: Cellular changes that are not yet cancerous but have a high probability of becoming malignant. Liquid Biopsy: A non-invasive test that detects cancer cells or DNA fragments (ctDNA) from a tumor circulating in the blood. Implementation Science: The study of methods to promote the integration of research findings and evidence-based practices into healthcare policy and routine practice. Computational Tools: The use of AI and machine learning to analyze medical imaging (CT/PET scans) for subtle patterns invisible to the human eye. Biomarker Validation: The process of proving that a specific biological marker reliably predicts the presence or progression of lung cancer. Who is Eligible? LCRF targets early-to-mid-career researchers to foster new leadership in the field. Primary Eligibility Criteria: Affiliation: Must be primarily affiliated with a non-profit academic or research institution. Career Stage: Post-doctoral researchers, clinical fellows, or early/mid-career investigators. Experience: Less than seven years since the initial faculty appointment. Global Reach: Open to both US-based and international institutions; all residency and citizenship statuses are welcome. Ineligibility and Restrictions: Senior investigators (>7 years post-appointment) are generally ineligible unless an exception is granted. Current LCRF grant recipients or those funded by LCRF within the last four years. Applicants may only apply to one LCRF funding track per cycle. Grant Funding and Financial Guidelines Total Award: $150,000 (disbursed as $75,000 per year). Duration: Two years. Allowable Costs: Salary support (with justification), project-specific travel, and publication fees. Prohibited Costs: Institutional indirect costs (overhead), administrative fees, and large general equipment purchases. Direct Care: Costs for patient care already reimbursable by other sources are not covered. How to Apply: Step-by-Step Instructions The LCRF utilizes a two-step competitive process to select high-impact projects. Step 1: Letter of Intent (LOI) Prepare a project summary focusing on prevention or early detection. Attach NIH Biosketch for the Primary Investigator and key personnel. Submit via the LCRF portal by March 10, 2026. Step 2: Full Proposal (By Invitation Only) If invited, provide a detailed scientific plan including rationale and feasibility. Include at least one Letter of Support from a program director or advisor. Ensure the letter confirms the availability of space, equipment, and institutional commitment. 2026 Program Timeline Letter of Intent (LOI) Deadline: March 10, 2026 LOI Decision Notification: April 28, 2026 Full Proposal Deadline: June 2, 2026 Award Notification: November 2026 Project Start Date: December 1, 2026 Common Mistakes and Tips Mistake: Including Indirect Costs. LCRF does not pay for institutional overhead. Ensure your budget reflects 100% direct research costs. Mistake: Broad Scope. “Early detection” is specific. Avoid proposals focused solely on late-stage therapeutic resistance unless it directly informs prevention. Tip: Focus on Disparities. Reviewers prioritize projects that address or reduce disparities in lung cancer outcomes. Tip: Early Contact. If you are a senior investigator with a unique case for eligibility, contact the LCRF grants office before the LOI deadline. Frequently Asked Questions (FAQ) 1. Does LCRF fund international researchers? Yes. Investigators from non-profit institutions worldwide are eligible to apply, regardless of their country of residence. 2. Can I use the grant to buy a new CT scanner or major lab equipment? No. Large, general equipment purchases are prohibited. Funds should be used for direct project costs and specific research needs. 3. What is the definition of “early-career” for this grant? LCRF defines this as having less than seven years of experience since your first faculty appointment. 4. Is a Letter of Intent mandatory? Yes. You cannot submit a full proposal unless your LOI has been reviewed and you have been formally invited to the next stage. 5. How are applications reviewed? Proposals undergo a three-tier review: administrative (compliance), scientific (peer-review), and patient advocate (impact and relevance). 6. Does this grant support Small Cell Lung Cancer (SCLC) research? Yes. The grant covers both Non-Small Cell (NSCLC) and Small Cell (SCLC) lung cancer research. 7. Can I apply for two different LCRF grants in the same year? No. Applicants are restricted to one funding track per cycle. Conclusion The LCRF Early Detection and Prevention Research Grant is a vital resource for investigators aiming to transform lung cancer from a late-stage crisis into a manageable, early-diagnosed condition. By adhering to the strict eligibility criteria and focusing on innovative biomarkers or implementation science, researchers can secure the funding necessary to move the needle on global lung cancer survival rates.